Refine your search
Collections
Co-Authors
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Dhole, Archana R.
- Herbal Therapy for Urolithiasis: A Brief Review
Abstract Views :593 |
PDF Views:0
Authors
Affiliations
1 Rajarambapu College of Pharmacy, Kasegaon, IN
1 Rajarambapu College of Pharmacy, Kasegaon, IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 5, No 1 (2013), Pagination: 6-11Abstract
Range of plants and plant-derived products are used in folk medicine for the treatment of urolithiasis as a prophylactic agent or as curative agent. Most of them found to be effective, but still the complete mechanism of action of these herbal drugs remains to be unclear. In present review we are discussing the, Diagnosis and various mechanism of action through which phytotheraeupatic agents exert their antiurolithiatic effect. Unlike allopathic medicines which targets only one aspect of urolithiatic pathophysiology, most of plant based therapy have been shown to be effective at different stages of stone pathophysiology.
Only a few studies have suggested some evidence for the efficacy of herbal medicines, however, most are not evidence-based. Some preclinical research has proved the efficacy of some of these herbs in urolithiasis. Precise understandings of the pathophysiology of disease and mechanism of action of these herbal medicines have great importance in development of effective and safe antiurolithiatic agent. Herbal medicines is efficacious and has lesser side effects compared to modern medicines and also reduce the recurrence rate of renal stone (4). Although the complete mechanism of action of these remedies are lacking but, plant based phytotherapeutic agents represent the majority used in medicine for urolithiatic.
Keywords
Urolithiatic, Stone Formation, Diagnosis and Various Mechanism of Action
References
- Riches E.. The history of lithotomy and lithotrity. Ann. R. Coll. Surg. Engl. 43;1968,:185
- Beck CW and Mulvaney WP. Apathitic urinary calculi from early American Indians. JAMA. 195;1996: 168-169
- Butt AJ. Etiologic factors in renal lithiasis, Thomson publishers, Springfield, Illinois, U.S.A. 1954: 3.
- Prasad, KV. Sujatha D and Bharti K, Herbal drugs in urolithiasis: A review. Pharmacog. Rev. 1: 175; 2007:179.
- Barry H. Antioxidant effects: A basis for drugselection.Drugs.42; 1991: 569-605.
- Narayana V and Ali VS. Pashanabheda. J. Res. Indian. Med. 1;1967:24
- Bahl and Seshadri. Advances in research in “Indian Medicine”, “Pashanbedi” drugs for urinary calculus, Udupa. K.N.(Eds),1970:77-98
- Mukherjee T. Neeraj B. Aulakh GS. And Jain HC.Herbal drugs for urinary stones- Literature appraisal. Indian drugs. 24; 1984: 224-228
- Fleisch H. Inhibitors and promoters of stone formation. Kidney Int 1978; 13: 361-71.
- Wells KA. Nephrolithiasis with Unusual Initial Symptoms. J Manipulative Physiol Therapy.23 (3); 2000: 196-201.
- Portis AJ, Sundaram CP. Diagnosis and Initial Management of Kidney Stones. Am Fam Physician. 63(7); 2001:329-38.
- Prasad KVSRG, Bharthi K, Srinivasan KK. Evalution of Ammania baccifera Linn. For antiurolithiatic activity in albino rate. Ind J Expt Biol. 32(5); 1994:311-13.
- Keler T, Jansen B, Hesse A. Effect of blackcurrant, cranberry and plum juice consumption on risk factors associated with kidney stone formation. Eur J Clin Nutr. 56; 2002: 1020-23.
- Bhaskar R, Varalakshmi P, Amsaveni R. Changes in tissue enzymes produced by Coleus aromaticus in experimental urolithiasis. Indian Drugs; 29;1992: 254-58.
- Viel TAJ, Domingos CD, Monteiro APS, Lima-Landman MTR, Lapa AJ, Souccar C. Evaluation of the antiurolithiatic activity of the extract of Costus spiralis Roscoe in rats. J Ethnopharmacol; 66; 1999:193–98.
- Harg TM, Rodgers A, Charlton K. Influence of cranberry juice on the urinary risk factors for calcium oxalate kidney stone formation. BJU Int. 92; 2003:765-68.
- Christiana AJ, Lakshmi MP, Nagarajan M, Kurian S. Modulatory effect of Cyclea pertata lam. On stone formation induced by ethylene glycol treatment in rats. Exp Clin Pharmacol.24; 2002:77-79.
- Atmani F, Slimani Y, Mimouni M, Aziz M, Hacht B, Ziyyat A. Effect of aqueous extract from Herniaria hirsute L. on experimentally nephrolithiasic rats. J Ethnopharmacol.95; 2004: 87–93.
- Grases F, Ramis M, Bauzi AC, March JG. Effect of Herniaria hirsuta and Agropyron repens on calcium oxalate urolithiasis risk in rats. J Ethnopharmacol.45; 1995: 211-14.
- Vidya L, Varalakshmi P. Control of urinary risk factors of stones by betulin and lupeol in experimental hyperoxaluria. Fitoterapia.71; 2000:535-43.
- Anand R, Patnaik GK, Roy K, Bhaduri AP. Antioxaluric and Anticalciuric activity of lupeol derivatives. Ind J Pharmacol. 27; 1995: 265-68.
- Karadi RV, Gadge NB, Alagawadi KR, Savadi RV. Effect of Moringa oleifera Lam. ischolar_main-wood on ethylene glycol induced urolithiasis in rats. J Ethnopharmacol. 105; 2006: 306–11.
- Prasad KVSRG, Bharathi K, Srinivasan KK. Evaluation of Musa (paradisica linn.cultivar)- “puttable” stem juice for antilithiatic activity in albino rats. Ind J Phy Pharmacol. 33; 1993: 337-41.
- Poonguzhali PK, Chegu H. The influence of banana stems extract on urinary risk factors for stones in normal and hyperoxaluric rats. Br J Urol.74; 1994: 23-25.
- Barros ME, Lima R, Mercuri LP, Matos JR, Schor N, Boim MA. Effect of extract of Phyllanthus niruri on crystal deposition in experimental urolithiasis. Urol Res. 34; 2006: 351-57.
- Murugaiyah V, Chan KL. Mechanisms of antihyperuricemic effect of Phyllanthus niruri and its lignin constituents. J Ethnopharmacol. 124; 2009: 233-39.
- Vargas SR, Perez GRM, Perez GS, Zavala. SMA, Perz GC. Antiurolithiatic activity of Raphanus sativus extract on rats. J Ethnopharmacol.68;1999: 335-38.
- Vargas R, Perez RM. Effect of aqueous extract of Salix taxifolia in experimentally induced urolithiatic rats. Pharm boil. 40 (8); 2002: 561-63.
- Anand R, Patnaik GK, Kulshreshtha DK, Dhawan BN. Activity of certain fractions of Tribulus terrestris fruits against experimentally induced urolithiasis in rats. Ind J Exp Biol. 32; 1994: 548-52.
- Sangeeta D, Sidhu H, Thind SK, Nath R. Effect of Tribulus terrestris on oxalate metabolism in rats. J Ethnopharmacol 1994; 44: 61-66.
- Ali MA, Wahbi S, Twaij H, Badr AA. Tribulus terrestris: preliminary study of its diuretic and contractile effects and comparison with Zea mays. J Ethnopharmacol.85; 2003: 257-60.
- Varalakshmi P, Shamila Y, Latha E. Effect of Crataeva nurvala in experimental urolithiasis. J Ethnopharmacol. 28; 1990: 313-21.
- Singh RG, Kapoor SU. Evaluation of antilithiatic properties of Varuna (Crataeva nurvala). J Res Edu Indian med. 10;1991: 35-39.
- Gupta P, Patel N, Bhatt L, Zambare GN, Bodhanka SLB. Nandakumar K. Anti-urolithiatic effects of petroleum ether extract stem bark of Crataeva adansonii DC. (Fam. Capparidaceae) in rats. Pharma Biol. 44(3); 2006: 160-65.
- Soundararajan P, Mahesh R, Ramesh T, Begum VH. Effect of Aerva lanata on calcium oxalate urolithiasis in rats. Ind J Exp Biol. 44; 2006: 981-86.
- Selvam R,Kalaiselvi P, Govindaraj A, Murugan VB, Kumar ASS. Effect of Aerva lanata leaf extract and vediuppu chunnam on the urinary risk factors of calcium oxalate urolithiasis during experimental hyperoxaluria. Pharmacol Res. 43(1); 2001: 89-93.
- Bashir S, Gilani AH. Antiurolithic effect of Bergenia ligulata rhizome: An explanation of the underlying mechanisms. J Ethnopharmacol. 122;2009: 106–16.
- Hadjzadeh MAR, Khoei A, Hadjzadeh Z, Parizady M. Ethanolic Extract of Nigella sativa L Seeds on Ethylene Glycol-Induced Kidney Calculi in Rats. Urology. 4(2); 2007: 86-90.
- Bahuguna YM, Rawat MSM, Juyal V, Gnanarajan G. Antilithiatic effect of grains of Eleusine Coracana. Saudi Pharma J. 17(2); 2009: 182-87.
- Prasongwatanaa V, Woottisin S, Sriboonlue P, Kukongviriyapan V. Uricosuric effect of Roselle (Hibiscus sabdariffa) in normal and renal-stone former subjects. J Ethnopharmacol. 117; 2008: 491–95.
- Moriyama MT, Suga K, Miyazawa K, Tanaka T, Higashioka M, Noda K, et al. Inhibitions of urinary oxidative stress and renal calcium level by an extract of Quercus salicina Blume/Quercus stenophylla Makino in a rat calcium oxalate urolithiasis model. Int J Urol. 16; 2009: 397-01.
- Khan ZA, Assiri AM, Al-Afghani HMA, Maghrabi TMA. Inhibition of oxalate nephrolithiasis with Ammi visnaga (AI-Khillah). Int Urol Nephrol. 33; 2001: 605-08.
- Atmani F, Sadki C, Aziz M, Mimouni M, Hacht B. Cynodon dactylon extract as a preventive and curative agent in experimentally induced nephrolithiasis. Urol Res. 37; 2009: 75-82.
- Dharmaraj S, Hossain MA, Zhari S, Harn GL, Ismail Z. The use of principal component analysis and self-organizing map to monitor inhibition of calcium oxalate crystal growth by Orthosiphon stamineus extract. Chemometrics and Intelligent Lab Sys.81; 2006: 21-28.
- Raut AA, Sunder S, Sarkar S, Pandita NS, Vaidya ADB. Preliminary study on crystal dissolution activity of Rotula aquatica, Commiphora wightii and Boerhaavia diffusa extracts. Fitoterapia.79; 2008: 544-47.
- Grases F, Ramis M, Costa-Bauzi A, March JG. Effect of Herniaria hirsuta and Agropyron repens on calcium oxalate urolithiasis risk in rats. J Ethnopharmacol. 45; 1995: 211-14.
- Swathi D, Sujatha D, Bharathi K, Prasad KVSRG. Antilithic activity of aqueous extract of ischolar_mains of Tephrosia purpurea Linn. Phcog mag. 4(16) ;2008: 206-11
- Drug used in Inflammatory Bowel Disease (IBD) - Brief Review
Abstract Views :263 |
PDF Views:0
Authors
Affiliations
1 Rajarambapu College of Pharmacy, Kasegaon, Tal.-Walva, Dist.-Sangli - 415 404, IN
1 Rajarambapu College of Pharmacy, Kasegaon, Tal.-Walva, Dist.-Sangli - 415 404, IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 6, No 3 (2014), Pagination: 153-161Abstract
Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract, which includes Crohn's disease (CD) and ulcerative colitis (UC). These diseases have become important health problems. Medical therapy for IBD has advanced dramatically in the last decade with the introduction of targeted biologic therapies, the optimization of older therapies, including drugs such as immunomodulators and 5-aminosalicylic acid (5-ASA), and a better understanding of the mucosal immune system and the genetics involved in the pathogenesis of IBD. The goal of IBD therapy is to induce and maintain remission. Drug delivery to the appropriate site(s) along the gastrointestinal tract also has been a major challenge, and second-generation agents have been developed with improved drug delivery, increased efficacy, and decreased side effect The current treatment paradigm involves a step-up approach, moving to aggressive, powerful therapies only when milder therapies with fewer potential side effects fail or when patients declare themselves to have an aggressive disease. This review focuses on the, symptoms, diagnosis and current treatments for inflammatory bowel disease.Keywords
Inflammatory Bowel Disease (IBD), 5-Aminosalicylates, Corticosteroids, Infliximab, Herbal Drugs, Symptoms, Diagnosis.References
- Longstreth GF. Definition and classification of irritable bowel syndrome: current consensus and controversies. Gastroenterol. Clin. North Am. 2005; 34: 173-87.
- Drossman DA. Introduction. The Rome Foundation and Rome III. Neurogastroenterol. Motil. 2007; 19: 783-6.
- WHO. International Statistical Classification of Diseases and Related Health Problems, 10th edn. Geneva, Switzerland: World Health Organization, 2007.
- Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. BMJ 1978; 2 (6138): 653-4.
- Brandt LJ, Bjorkman D, Fennerty MB et al. Systematic review on the management of irritable bowel syndrome in North America. Am. J. Gastroenterol. 2002; 97 (11 Suppl.): S7-26.
- Drossman DA, Douglas A, eds. Rome III: The Functional Gastrointestinal Disorder, 3rd edn.
- McClean, VA, USA: Degnon Associates, 2006. 7 Thompson WG, Irvine EJ, Pare P, Ferrazzi S, Rance L. Functional gastrointestinal disorders in Canada: first population-based survey using Rome II criteria with suggestions for improving the questionnaire. Dig. Dis. Sci. 2002; 47: 225-35.
- Talley NJ, Zinsmeister AR, Melton LJ 3rd. Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Am. J. Epidemiol. 1995; 142: 76-83.
- Cash BD, Chey WD. Diagnosis of irritable bowel syndrome. Gastroenterol. Clin. North Am. 2005; 34: 205-20.
- Lea R, Whorwell PJ. The role of food intolerance in irritable bowel syndrome. Gastroenterol. Clin. North Am. 2005; 34: 247-55.
- Palsson OS, Drossman DA. Psychiatric and psychological dysfunction in irritable bowel syndrome and the role of psychological treatments. Gastroenterol. Clin. North Am. 2005; 34: 281-303.
- Cash BD, Chey WD. Irritable bowel syndrome-an evidence based approach to diagnosis. Aliment. Pharmacol. Ther. 2004; 19: 1235-45.
- Park JM, Choi MG, Kim YS et al. Quality of life of patients with irritable bowel syndrome in Korea. Qual. Life. Res. 2009; 18: 435-46.
- Katsinelos P, Lazaraki G, Kountouras J et al. Prevalence, bowel habit subtypes and medical care-seeking behaviour of patients with irritable bowel syndrome in Northern Greece. Eur. J. Gastroenterol. Hepatol. 2009; 21: 183-9.
- Tan YM, Goh KL, Muhidayah R, Ooi CL, Salem O. Prevalence of irritable bowel syndrome in young adult Malaysians: a survey among medical students. J. Gastroenterol. Hepatol. 2003; 18: 1412-16.
- Hillila MT, Farkkila MA. Prevalence of irritable bowel syndrome according to different diagnostic criteria in a non-selected adult population. Aliment. Pharmacol. Ther. 2004; 20: 339-45.
- Bommelaer G, Dorval E, Denis P et al. Prevalence of irritable bowel syndrome in the French population according to the Rome I criteria. Gastroenterol. Clin. Biol. 2002; 26: 1118-23.
- World Gastroenterology Organization, 2009 WGO Global Guideline IBD4
- Barnes PJ, Karin M: Nuclear factor-_B. A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med, 1997, 336, 1066-1071.
- Prantera C, Cottone M, Pallone F: Mesalamine in the treatment of mild to moderate active Crohn's ileitis, results of a randomised multicenter trial. Gastroenterology, 1999, 116, 521-52.
- Camma C, Giunta M, Rosselli M, Cottone M: Mesalamine in the maintenance treatment of Crohn's disease, A meta-analysis adjusted for confounding variables. Gastroenterology, 1997, 113, 1465-1473.
- Wahl C, Liptay S, Adler G, Schmid RM: Sulfasalazine, a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest, 1998, 101, 1163-1174.
- Meyers S, Sachar DB: Medical therapy of Crohn's disease. In: Inflammatory Bowel Disease. 4th edn., Eds. Kersnar JB, Shorter RG, Williams and Wilkins, Baltimore, 1995, 695-714.
- Aberra FN, Lewis JD, Hass D, Rombeau J, Osborne B, Lichtenstein G: Corticosteroids and immunomodulators, postoperative infectious complication risk in inflammatory bowel disease. Gastroenterology, 2003, 125, 320-327.
- Bello C, Goldstein F, Thornton JJ: Alternate-day prednisone treatment and treatment maintenance in Crohn's disease. Am J Gastroenterol, 1991, 86, 460-466.
- Faubion WA Jr, Loftus EV, Harmsen WS, Zinmeister AR, Sandborn WJ: The natural history of corticosteroid therapy for inflammatory bowel disease, a population based study. Gastroenterology, 2001, 121, 255-260.
- Vakil N, Sparberg M: Steroid-related osteonecrosis in inflammatory bowel disease. Gastroenterology, 1989, 96, 62-67.
- Greenberg GR, Feagan BR, Martin F, Sutherland L, Thomson A,Williams N, Nilsson L, Persson T: Oral budesonide for active Crohn's disease. New Eng J Med, 1994, 331, 836-841.
- Hofer KN: Oral budesonide in management of Crohn's disease. Ann Pharmacother, 2003, 37, 1457-1464.
- Aberra FN, Lewis JD, Hass D, Rombeau J, Osborne B, Lichtenstein G: Corticosteroids and immunomodulators, postoperative infectious complication risk in inflammatory bowel disease. Gastroenterology, 2003, 125, 320-327.
- Fernandes-Banares F, Hinojoso J, Sanchez-Lombrana JL: Randomised clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Am J Gastroenterol, 1999, 2, 427-433.
- Sandborn WJ: A critical review of cyclosporine therapy in inflammatory bowel disease. Inflamm Bowel Dis, 1995, 1, 48-63.
- Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present D, Braakman T, DeWoody K et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor - for Crohn's disease. New Eng J Med, 1997, 337, 1029-1035.
- Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S: Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med, 2007, 357, 228-238.
- Watt K, Christofi N, Young R. The detection of antibacterial actions of whole herb tinctures using luminescent Escherichia coli. Phytother Res 2007; 21: 1193-1199.
- Yoshikawa M, Morikawa T, Oominami H, Matsuda H. Absolute stereo structures of olibanumols A, B, C, H, I, and J from olibanum, gum-resin of Boswellia carterii, and inhibitors of nitric oxide production in lipopolysaccharide-activated mouse peritonea macrophages. Chem Pharm Bull (Tokyo) 2009; 57: 957-964
- Chevrier MR, Ryan AE, Lee DY, Zhongze M, Wu-Yan Z, Via CS. Boswellia carterii extract inhibits TH1 cytokines and promotes TH2 cytokines in vitro. Clin Diagn Lab Immunol 2005; 12: 575-580
- Camarda L, Dayton T, Di Stefano V, Pitonzo R, Schillaci D. Chemical composition and antimicrobial activity of some oleogum resin essential oils from Boswellia spp. (Burseraceae). Ann Chim 2007; 97: 837-844.
- Moghtader M, Mansouri I, Salari H, Farahmand A. Chemical composition and antimicrobial activity of the essential oil of bunium persicum boiss. Seed. Iran J Med Aromat Plants Spring 2009; 25: 20-28.
- Shahsavari N, Barzegar M, Sahari MA, Naghdibadi H. Antioxidant activity and chemical characterization of essential oil of Bunium persicum. Plant Foods Hum Nutr 2008; 63: 183-188.
- Kumar VP, Chauhan NS, Padh H, Rajani M. Search for antibacterial and antifungal agents from selected Indian medicinal plants. J Ethnopharmacol 2006; 107: 182-188.
- Francis JA, Raja SN, Nair MG. Bioactive terpenoids and guggulusteroids from Commiphora mukul gum resin of potential anti-inflammatory interest. Chem Biodivers 2004; 1: 1842-1853.
- Saeed MA, Sabir AW. Antibacterial activities of some constituents from oleo-gum-resin of Commiphora mukul. Fitoterapia 2004; 75: 204-208.
- Preparation of Novel Biocompatible Honey Hydrogel with Turmaric and Aloe vera
Abstract Views :272 |
PDF Views:6
Authors
Affiliations
1 Rajarambapu College of Pharmacy, Kasegaon. Tal-Walwa, Dist Sangli, Maharashtra, IN
1 Rajarambapu College of Pharmacy, Kasegaon. Tal-Walwa, Dist Sangli, Maharashtra, IN